Skip to main content
HR 3677 106th Congress House

Thomas Navarro FDA Patient Rights Act

Official title: To amend the Federal Food, Drug, and Cosmetic Act to restrict the authority of the Food and Drug Administration to issue clinical holds regarding investigation… Show full official titleShow less

Official title: To amend the Federal Food, Drug, and Cosmetic Act to restrict the authority of the Food and Drug Administration to issue clinical holds regarding investigational drugs or to deny patients expanded access to such drugs.

Introduced: February 16, 2000 See on congress.gov
Health Access to health careClinical trialsDrug approvalsDrugs
More subjectsShow fewer subjects
Informed consent (Medical law)LawPatients' rightsPharmaceutical researchScience, Technology, Communications
Sign in to write a letter Sign in to watch
This bill died when the 106th Congress ended
It never became law before the 106th Congress (1999–2000) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 4 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Dec 15, 2000
Sponsor introductory remarks on measure. (CR E2230-2231)
Feb 23, 2000
Referred to the Subcommittee on Health and Environment.
Feb 16, 2000
Referred to the House Committee on Commerce.
Feb 16, 2000
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action December 15, 2000

Sponsor introductory remarks on measure. (CR E2230-2231)

 Plain-English summary Congressional Research Service
Thomas Navarro FDA Patient Rights Act - Amends the Public Health Service Act to prohibit the Secretary of Health and Human Services from placing a clinical hold on an investigation of a drug on the basis that the Secretary has determined that: (1) there is another drug (including another investigational drug) that is or may be a safe and effective therapy for the disease or condition involved; or (2) there is a comparable or satisfactory alternative therapy available for a patient who is receiving or will receive the drug as a clinical subject in the investigation, subject to exception.
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 2
 Cosponsors 3
All 3 Democratic 1 Republican 1
D
Pallone, Frank
New Jersey · Jul 27, 2000
 R
Calvert, Ken
California · Jul 26, 2000
Sanford, Mark
· Jun 6, 2000
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 3677: Thomas Navarro FDA Patient Rights Act. 106th Congress. Open America. https://openamerica.io/bill/106-HR-3677/
MLA
"H.R. 3677: Thomas Navarro FDA Patient Rights Act." 106th Congress, 2026, Open America, https://openamerica.io/bill/106-HR-3677/.
Bluebook (legal)
H.R. 3677, 106th Cong. (2026), https://openamerica.io/bill/106-HR-3677/.
Markdown link
[H.R. 3677: Thomas Navarro FDA Patient Rights Act](https://openamerica.io/bill/106-HR-3677/)
Report a problem